This website is intended for healthcare professionals only

Trending Topic

3 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

It is with great pleasure that we present the latest edition of touchREVIEWS in Oncology & Haematology. This issue reflects the growing momentum of precision oncology, from liquid biopsy and response-adapted strategies to antibody–drug conjugates (ADCs) and immune-based therapies, alongside the challenges of translating these advances into routine, equitable care. We open with an editorial […]

Search Results

454 Results Found for “Aged 80 and over”

Speciality Filter

Select Specialty or Clinical Area

Clear All
Update Filters
Close Popup
Mark CompleteCompleted
BookmarkBookmarked

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma in the USA and Western Europe.1,2 DLBCL is treated with curative intent given the aggressive nature of the disease. Rituximab (R), cyclophosphamide (C), doxorubicin (H), vincristine (O) and prednisone (P) (...

Mark CompleteCompleted
BookmarkBookmarked

Gastrointestinal (GI) cancers constitute a major contributor to global cancer incidence and mortality and remain among the leading causes of cancer-related death worldwide despite advances in prevention, screening and supportive care.1,2 Collectively encompassing malignancies of the esophagus, stomach, liver, biliary ...

Human kidneys and bladder anatomical medical 3d render illustration
Mark CompleteCompleted
BookmarkBookmarked
Amena Ahmad, Oskar Lepiarczyk, Alison Birtle

Urothelial carcinoma (UC) is the 11th most common cancer in the UK, with approximately 11,000 new bladder cancer diagnoses annually.1 Globally, bladder cancer accounts for approximately 635,000 new diagnoses and 228,000 deaths annually, based on the latest GLOBOCAN estimates for 2024.2 Bladder cancer constitutes ...

medical illustration concept symbol as a group of human blood cells
Mark CompleteCompleted
BookmarkBookmarked

For almost two decades, R-CHOP has remained the established frontline standard for DLBCL, yet approximately 40% of patients are not cured with first-line therapy. At EHA 2026, Prof Georg Lenz presented new phase 3 data from the frontMIND study suggesting that this long-standing backbone may now be open to improvement. The study showed that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival (PFS) in previously untreated patients with high-risk DLBCL and high-grade B-cell lymphoma (HGBL), marking one of the first positive frontline intensification trials in this setting in recent years.

Mark CompleteCompleted
BookmarkBookmarked

Extended follow-up from the phase 3 INDIGO trial presented at ASCO 2026 provides further evidence that vorasidenib may offer durable disease control in patients with grade 2 glioma harboring IDH1/2 mutations, reinforcing earlier findings that led to its regulatory approvals. In the article below, we provide a details analysis of the latest INDIGO data and Dr Timothy Cloughesy's expert perspective on what the longer-term efficacy and safety findings could mean for the evolving treatment landscape in IDH-mutant glioma.

Inflammation of the breast in women. Female breasts with signs of the disease. A low-poly construction of interconnected lines and points. Blue background.
Mark CompleteCompleted
BookmarkBookmarked
Coverage from: ASCO 2026
Rupert Bartsch

Dr Rupert Bartsch (University of Vienna, Austria) highlighted six important studies across the breast cancer landscape presented at ASCO 2026. The studies below discuss interesting and strategic developments in genomic risk stratification in early disease, supportive care optimization, HER2-positive metastatic strategies and novel antibody–drug conjugates in triple-negative breast cancer.

Mark CompleteCompleted
BookmarkBookmarked

Among the emerging voices at the 7th SIOP Europe Annual Meeting, was Dr Miguel Vieira-Martins, (Princess Máxima Center, Utrecht, Netherlands and member of Young SIOPE Steering Committee). He is deeply engaged in both the scientific and collaborative structures driving the field forward. In this interview, he discusses how opportunities in Young SIOPE are supporting early-career professionals, and reflects on the importance of international networks, the rise of immunotherapy and how meetings like SIOPE are accelerating progress from bench to bedside.

3d medical illustration of lung cancer
Mark CompleteCompleted
BookmarkBookmarked
Christopher R Pallas, Daniel R Carrizosa, Kathryn F Mileham

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality worldwide.1 Over the past two decades, the molecular characterization of NSCLC has transformed the therapeutic landscape by enabling the development of targeted therapies that have significantly improved outcomes ...

Dermatologist examining the skin of a patient; panoramic banner
Mark CompleteCompleted
BookmarkBookmarked

An immunosuppressed person is one whose immune function is impaired by underlying disease and/or immunosuppressive medications, resulting in reduced immunosurveillance against malignant cells and increased vulnerability to opportunistic infections. Longstanding immunosuppression has been linked to increased risk for cutaneous (...

A Detailed 3D Depiction Of The Small Intestines Of A Human Female
Mark CompleteCompleted
BookmarkBookmarked

Small bowel adenocarcinoma (SBA) is a rare gastrointestinal malignancy, accounting for about 1–3% of gastrointestinal cancers.1,2 Its reported incidence has increased in recent decades, likely reflecting improved detection by balloon-assisted and capsule endoscopy and the more widespread use of cross-sectional imaging.3,4 ...

Mark CompleteCompleted
BookmarkBookmarked

In this Future Leaders interview, Margaret Wheless reflects on the mentors who shaped her career, the fulfillment she finds in patient care and teaching, and the importance of empathy, collaboration, and intentional mentorship for emerging oncologists.

Mark CompleteCompleted
BookmarkBookmarked

In this touchONCOLOGY Future Leaders 2026 interview, Dr Lenz reflects on the mentorship that shaped his commitment to oncology, the role of research in exposing inequities in cancer care, and why ensuring equitable access to innovation will define the future of the field.

Mark CompleteCompleted
BookmarkBookmarked

In this Future Leaders interview, Dr Di Carlo reflects on the mentors who shaped her career, the lessons of resilience and authenticity she carries forward, and the importance of aligning personal values with patient-centered care and lifelong learning in oncology.

Microscopic macro view of pancreatic cancer cells showing abnormal cell structure irregular nuclei aggressive growth inside glandular tissue dark medical background
Mark CompleteCompleted
BookmarkBookmarked
Sakhr Alshwayyat, Noor Almasri, Karam Maraqa

Pancreatic cancer (PC) is the tenth most common cancer in 2024, with 66,440 new cases and 51,570 deaths.1,2 Globally, the prevalence varies from 10/100,000 cases in the Americas and Europe to 0.9/100,000 cases in South Central Asia and most of Africa.3 Currently, it has the ...

Mark CompleteCompleted
BookmarkBookmarked

We are counting down to the launch of touchONCOLOGY Future Leaders 2026 – a celebration of the rising stars shaping the future of cancer care.

Mark CompleteCompleted
BookmarkBookmarked

At ESGO26 investigators answered some of the field’s most persistent questions: the optimal timing of surgery, chemotherapy scheduling, the promise of immunotherapy in platinum-resistant disease and how molecular profiling can sharpen surgical decision-making. And the results didn't disappoint. Below are four of the most important abstracts from the Late-breaking, Best Oral and Best Three Minutes sessions: ENGOT-ov65/KEYNOTE-B96, RACC, ACR-368-201 and EUGENIE revealed insights that could shift the standard of care. Here’s what you need to know.

Macro image of a needle being pricked at a cancer cell. Research of cancer diseases, viruses in infected organism , viral disease epidemic, vaccine background.
Mark CompleteCompleted
BookmarkBookmarked
Rafael Alvim Pereira, Milena Tumelero, Wallace Klein Schwengber

Immune checkpoint inhibitors (ICIs) act by blocking inhibitory pathways such as programmed cell death protein 1 (PD-1), programmed cell death ligand 1 (PD-L1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), thereby restoring T-cell activity and promoting tumour cell destruction.1,2 The ability of tumours ...

Mark CompleteCompleted
BookmarkBookmarked

Project Cure CRC, a $100 million initiative by the Colorectal Cancer Alliance (Alliance), continues to revolutionize colorectal cancer research by announcing three new groundbreaking grants aimed at transforming patient care. To date, Project Cure CRC has reviewed more than 500 research proposals and invested nearly $13 million to fuel 32 innovative studies. Several grantees have already published progress from their work in prestigious scientific journals, reflecting the program’s impact on advancing the field. As the largest nonprofit dedicated to ending colorectal cancer, the Alliance is prioritizing Project Cure CRC to accelerate the development of cutting-edge treatments that improve outcomes for patients worldwide.

Load More...
Close Popup